Donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline
The Pharma Data
JULY 29, 2021
Additionally, pharmacokinetic/pharmacodynamic modeling showed that greater relative amyloid plaque clearance was correlated with greater clinical benefit. Lilly plans to submit a biologics license application (BLA) for donanemab under the accelerated approval pathway later this year.
Let's personalize your content